← Beam Therapeutics Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $18k |
$24k
+33.33%
|
$51.8m
+215916.67%
|
$60.9m
+17.51%
|
$377.7m
+520.01%
|
$63.5m
-83.18%
|
$139.7m
+120.01%
|
$156.0m
+11.66%
|
|
| Research and development | $54.6m | $103.2m | $387.1m | $311.6m | $437.4m | $367.6m | $409.6m | $408.7m | |
| General and administrative | $20.6m | $29.6m | $57.2m | $87.8m | $116.8m | $111.5m | $113.8m | $125.4m | |
| Total operating expenses | $75.2m | $132.8m | $444.3m | $399.4m | $554.2m | $479.1m | $523.4m | $534.1m | |
| Loss from operations | ($75.2m) |
($132.8m)
-76.65%
|
($392.5m)
-195.62%
|
($338.5m)
+13.76%
|
($176.5m)
+47.86%
|
($415.6m)
-135.47%
|
($383.7m)
+7.67%
|
— | |
| Gain on sale of equity method investment | — | — | ($370.6m) | ($25.5m) | $0 | $0 | $255.1m | — | |
| Unrealized gain (loss) on marketable securities | $16k | ($25k) | ($41k) | ($2.4m) | $3.0m | $75k | $432k | — | |
| Interest and other income (expense), net | $2.2m | $1.6m | ($9k) | $15.3m | $46.7m | $49.1m | $43.7m | — | |
| Total other income (expense) | ($3.2m) | ($61.8m) | $21.8m | $78.3m | $45.3m | $38.9m | $303.7m | — | |
| Net loss before income taxes | ($78.3m) | ($194.6m) | ($370.6m) | ($260.2m) | ($131.2m) | ($376.7m) | ($80.0m) | — | |
| Provision for income taxes | — | $0 | $0 | ($3.4m) | ($1.4m) | ($39k) | $0 | — | |
| Net loss | ($78.3m) | ($194.6m) | ($370.6m) | ($289.1m) | ($132.5m) | ($376.7m) | ($80.0m) | — | |
| Net loss per common share, basic | ($14) | ($4) | ($6) | ($4) | ($2) | ($5) | ($1) | — | |
| Net loss per common share, diluted | ($14) | ($4) | ($6) | ($4) | ($2) | ($5) | ($1) | — | |
| Weighted - average common shares outstanding, basic | 6.5m | 46.7m | 64.2m | 70.0m | 77.2m | 82.3m | 98.9m | — | |
| Weighted - average common shares outstanding, diluted | 6.5m | 46.7m | 64.2m | 70.0m | 77.2m | 82.3m | 98.9m | — | |
| Change in fair value of derivative liabilities | ($5.4m) | ($63.4m) | ($1.0m) | $23.9m | $7.5m | $2.3m | $700k | — | |
| Change in fair value of non-controlling equity investments | — | $517k | $17.7m | $20.2m | ($18.6m) | ($14.1m) | $3.9m | — | |
| Change in fair value of contingent consideration liabilities | — | ($194.6m) | $5.1m | $18.9m | $9.7m | $1.6m | $180k | — | |
| Comprehensive loss | ($78.3m) | ($194.6m) | ($370.7m) | ($291.5m) | ($129.5m) | ($376.7m) | ($79.6m) | — |